Daraxonrasib, an investigational oral inhibitor of the RAS oncogene, doubled the median survival of patients with metastatic pancreatic adenocarcinoma. The drug was tested in the international phase 3 RASoute 302 study. The results were presented at the American Society of Clinical Oncology congress, in Chicago, and published simultaneously in New England Journal of Medicine.
The trial randomized 500 already treated patients. Desses, 248 received daraxonrasib and 252 underwent standard chemotherapy. Median survival reached 13.2 months in the new drug group. In the control arm, the rate was 6.7 months. The reduction in the risk of death reached 60%.
Apresentação generates applause at ASCO congress
The ASCO 2026 plenary session registered an unusual reaction. Study coordinator Brian M. Wolpin of Dana-Farber Cancer Institute displayed the mortality reduction data. The auditorium reacted with applause that lasted 42 seconds.
Médicos present expressed enthusiasm. The result represents a significant advance for a disease with limited therapeutic options until now. Advanced stage pancreatic cancer has an unfavorable prognosis in most cases.
Mecanismo of daraxonrasib silences RAS mutation
Daraxonrasib acts as a multiselective RAS(ON) inhibitor. Ele blocks the activated form of the oncogene, responsible for uncontrolled growth in more than 90% of pancreatic tumors.
The medication is administered as a 300 mg oral tablet once a day. Diferente of previous treatments, it manages to reach a target considered for decades as “non-pharmacological”. The FDA has granted breakthrough therapy designation for KRAS G12X mutations.
Efeitos side effects and treatment tolerability
Participants in the daraxonrasib study reported skin rash and stomatitis as main adverse events. Esses effects were considered tolerable in most cases.
The discontinuation rate due to toxicity was 1.2% in the experimental arm. In the chemotherapy group, the rate rose to 11.2%. Eventos serious adverse events were also less frequent with the new drug.
- Redução 60% risk of death
- Sobrevida progression free 7.2 months versus 3.6 months
- Taxa objective response of 31.6% versus 11.2% in chemotherapy
- Melhora on patient-reported quality of life
- Perfil manageable security in continuous use
Revolution Medicines leads therapy development
Revolution Medicines, a company specializing in targeted treatments for RAS-dependent tumors, is leading the development. Daraxonrasib emerges as the company’s main candidate.
Especialistas assess that the result could change the standard of care in the second line. Jennifer J. Knox of Princess Margaret Cancer Centre highlighted the future role of RAS inhibitors across the spectrum of pancreatic disease.
Impacto for patients with few alternatives
Metastatic pancreatic adenocarcinoma responds poorly to conventional chemotherapies. Most patients survive less than a year after progression. The new data opens up the prospect of additional months with better symptom control.
Future Estudos should test daraxonrasib in earlier lines of the disease. Combination with other agents is also under evaluation. Global Reguladores must receive the data for approval review.
The RASoute 302 trial enrolled sites in América of Norte, Europa, and Ásia. The population included a large proportion of patients with RAS G12 mutations. The benefits remained consistent in the total group, regardless of the mutation identified.
Próximos steps after phase 3 results
Revolution Medicines plans to submit the dossier to regulatory agencies. The expectation is for a priority review of the Estados Unidos.
Oncologistas follows developments closely. The advance marks a turning point in the treatment of one of the most aggressive cancers. Pesquisas continue to extend the benefit to more patients.